Status:
COMPLETED
Study on Benefits of Therapy With Nifurtimox in Chagas Disease, a Parasitic Illness Mostly Transmitted to Humans by a Bug, Using Information From Patient Medical Records in Argentina
Lead Sponsor:
Bayer
Conditions:
Chagas' Disease
Eligibility:
All Genders
Brief Summary
The researchers in this trial want to analyze prerecorded patient data which provide information on benefits of the drug nifurtimox in patients with a sudden (acute) and long lasting (chronic) Chagas´...
Eligibility Criteria
Inclusion
- Male and female patients aged ≥0 years at time of diagnosis with Chagas' disease
- Diagnosis of Chagas' disease confirmed by parasitological and/or serological method(s) before start of antitrypanosomal treatment or during the course of this antitrypanosomal treatment cycle for the first episode recorded.
Exclusion
- Treatment with antitrypanosomal agent(s) other than nifurtimox, including experimental investigational products for Chagas' disease or antitrypanosomal combination treatment
- Patients with known evidence of organ manifestation of chronic Chagas' disease, e.g.Chagas' disease-related cardiomyopathy/heart disease, Chagas' disease-related digestive disease at time of primary diagnosis.
Key Trial Info
Start Date :
December 14 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 6 2020
Estimated Enrollment :
3000 Patients enrolled
Trial Details
Trial ID
NCT03784391
Start Date
December 14 2018
End Date
April 6 2020
Last Update
April 8 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Many locations
Multiple Locations, Argentina